Vimarsana
Biggest News Aggregation in the World

Page 40 - Accessed May News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed May. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed May Today - Breaking & Trending Today

AD Classics: Rosenthal Center for Contemporary Art / Zaha Hadid Architects - Vimarsana News

AD Classics: Rosenthal Center for Contemporary Art / Zaha Hadid Architects

Completed in 2003 in Cincinnati, United States. The belief that a building can both blend in and stand out at the same time is embodied by the Lois and Richard Rosenthal Center for Contemporary Art...

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio - Vimarsana News

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio

/PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs....

AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST) - Vimarsana News

AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy...

Take the legwork out of drug toxicity screening - Vimarsana News

Take the legwork out of drug toxicity screening

BioPharma

Global Blood Therapeutics, Inc.: MHRA Grants Marketing Authorization for GBT's Oxbryta (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older - Vimarsana News

Global Blood Therapeutics, Inc.: MHRA Grants Marketing Authorization for GBT's Oxbryta (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell diseaseSOUTH SAN FRANCISCO, Calif., July